Cargando…
Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study
Purpose: The study aims to retrospectively investigate the efficacy and safety of sorafenib combined with transarterial chemoembolization (TACE) (TACE+Sor) vs. TACE combined with sorafenib plus immune checkpoint inhibitors (TACE+Sor+ICIs) in treating intermediate and advanced TACE-refractory hepatoc...
Autores principales: | Zheng, Liyun, Fang, Shiji, Wu, Fazong, Chen, Weiqian, Chen, Minjiang, Weng, Qiaoyou, Wu, Xulu, Song, Jingjing, Zhao, Zhongwei, Ji, Jiansong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843459/ https://www.ncbi.nlm.nih.gov/pubmed/33521054 http://dx.doi.org/10.3389/fmolb.2020.609322 |
Ejemplares similares
-
A Radiomics Signature-Based Nomogram to Predict the Progression-Free Survival of Patients With Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation
por: Fang, Shiji, et al.
Publicado: (2021) -
TACE responser NDRG1 acts as a guardian against ferroptosis to drive tumorgenesis and metastasis in HCC
por: Tang, Bufu, et al.
Publicado: (2023) -
Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020) -
ZFP36 Binds With PRC1 to Inhibit Tumor Growth and Increase 5-Fu Chemosensitivity of Hepatocellular Carcinoma
por: Chen, Weiqian, et al.
Publicado: (2020) -
Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis
por: Zhang, Leida, et al.
Publicado: (2014)